Stock was down 9% on Fri-
I missed this)
Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 07:44 IOVA Iovance Biotherapeutics announced additional clinical data for its tumor infiltrating lymphocyte, TIL, therapy LN-145 in patients with metastatic non-small cell lung cancer, NSCLC, who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. The results are available in a poster at the Society for Immunotherapy of Cancer, SITC, Annual Meeting, November 12-14, 2021, Washington, D.C. and virtual. The results demonstrate the feasibility of TIL cell therapy in heavily pre-treated patients with NSCLC, and warrant continued investigation of LN-145 as a single-agent and in combination in patients with mNSCLC in ongoing Iovance clinical studies IOV-LUN-202 and IOV-COM-202. Following one-time treatment with LN-145 monotherapy, the overall response rate is 21.4% in the full analysis set and 25% in the efficacy-evaluable set, including one complete response and five partial responses. Two responders, including the CR, had PD-L1 negative tumors and two responders had tumors with KRAS mutations. One complete response and one partial response are ongoing at 20.7 months and 3.0 months, respectively, at a median study follow up of 9.8 months. The treatment-emergent adverse event profile is consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and IL-2. The heavily pre-treated patients in Cohort 3B had received a median of 2 prior therapies. All patients had progressed on prior immune checkpoint inhibitor therapy and all six responders received prior chemotherapy. TIL were most commonly grown and manufactured from tumor samples resected from the lung. Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, "We are pleased to present our clinical data for LN-145 in metastatic non-small cell lung cancer to the physician community at SITC. There remains a very significant unmet need to increase response rates and prolong survival in the second-line non-small cell lung cancer treatment setting. The data for LN-145 in this signal-finding cohort demonstrated the potential for TIL in metastatic non-small cell lung cancer across a diverse set of patients and informed our ongoing IOV-LUN-202 clinical study in second-line lung cancer. Iovance is committed to advancing both TIL alone and TIL combinations to address multiple non-small cell lung cancer patient populations." Iovance is currently enrolling patients in the IOV-LUN-202 clinical study to investigate LN-145 in second-line mNSCLC where patients have progressed on prior ICI and chemotherapy.
CC to save?
